Apriori Bio

• 09/07/2024
• Unknown
• $1,100,000

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants.

Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

Related People

Lovisa AfzeliusCo Founder

United States - Belmont, Massachusetts

Lovisa Afzelius is an origination partner at Flagship Pioneering. Lovisa has held or holds leadership positions such as CEO, co-founder, president, chairman of the board, and executive director across emerging biotech companies as well as large pharma. A computational scientist by training, she brings two decades of leadership experience and a passion for data-driven drug discovery, from early inception to clinical development across multiple therapeutic areas. Business delivery oriented, ambitious and highly motivated individual with excellent track-record of developing and executing complex strategic and operational plans across boundaries in a global matrix organization.

LinkedIn https://www.linkedin.com/in/lovisa-afzelius-9823628/